Skip to content
Home
Discovering Seelos
Our Focus
Our Seelos Management Team
Our Board of Directors
Careers
Pipeline
SLS-002 (intranasal ketamine)
Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD)
SLS-003 (sublingual ketamine)
SLS-004 (gene therapy)
SLS-005 (trehalose)
SLS-007 (peptidic inhibitor)
Patients and Caregivers
Investors and Media
Overview and Financials
Corporate Governance
Press Releases
SEC Filings
Stock Information
Home
Discovering Seelos
Our Focus
Our Seelos Management Team
Our Board of Directors
Careers
Pipeline
SLS-002 (intranasal ketamine)
Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD)
SLS-003 (sublingual ketamine)
SLS-004 (gene therapy)
SLS-005 (trehalose)
SLS-007 (peptidic inhibitor)
Patients and Caregivers
Investors and Media
Overview and Financials
Corporate Governance
Press Releases
SEC Filings
Stock Information
Month:
March 2022
March 10, 2022: HEALEY ALS Platform Trial Weekly Q&A Webinar with Warren Wasiewski, MD of Seelos Therapeutics and Shafeeq Ladha, MD, Regimen E Co-Lead, discussing the science behind trehalose (SLS-005)
March 12, 2022
Search for:
Recent Posts
Fireside Chat Replay from B. Riley Securities’ Virtual Neuro and Ophthalmology Conference on 4/27/2022
Fireside Chat Replay: Current Treatment of Acute Suicidal Ideation and Behavior and Discussion on the Market Potential for Seelos Therapeutics’ SLS-002 Program from 4/25/2022
March 10, 2022: HEALEY ALS Platform Trial Weekly Q&A Webinar with Warren Wasiewski, MD of Seelos Therapeutics and Shafeeq Ladha, MD, Regimen E Co-Lead, discussing the science behind trehalose (SLS-005)
Archives
April 2022
March 2022
October 2021
June 2021
April 2019
March 2019
February 2019
December 2018